Iterum Therapeutics Plc (ITRM)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Iterum Therapeutics Plc (ITRM)

Company Performance

Current Price

as of Oct 16, 2024

$1.03

P/E Ratio

N/A

Market Cap

$23.39M

Description

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Metrics

Overview

HQDublin, DU
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerITRM
Price$1.03+0.98%

Trading Information

Market Cap$23.39M
Float96.67%
Average Daily Volume (1m)187,859
Average Daily Volume (3m)282,030
EPS-$2.00

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income-$5.00M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$3.97M

EV$28.86M
EV/RevenueN/A
P/EN/A
P/SN/A
P/BN/A

Documents

Earnings Calls

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report 2023Q4

Earnings Report (2023-11-14)

Earnings Report (2023-08-11)

Factset

Factset Business Description

Factset Street Account

Iterum Therapeutics reports Q3 EPS ($1.20) ex-items vs year-ago ($0.43) ($0.77, 0.00) (2023-11-14T12:08:39Z)

Iterum Therapeutics announces completion of enrollment in REASSURE Phase 3 clinical trial of oral sulopenem in uncomplicated urinary tract infections ($0.66, 0.00) (2023-10-24T12:03:18Z)